


KIN1408

Cat. No.:	HY-19961		
CAS No.:	1903800-11-2		
Molecular Formula:	C ₂₅ H ₁₉ F ₂ N ₃ O ₃ S		
Molecular Weight:	479.5		
Target:	HCV; Flavivirus; Dengue virus		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 39 mg/mL (81.33 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration			
	1 mM	2.0855 mL	10.4275 mL	20.8551 mL
	5 mM	0.4171 mL	2.0855 mL	4.1710 mL
	10 mM	0.2086 mL	1.0428 mL	2.0855 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses^{[1][2]}.

In Vitro

KIN1408 has the potency to drive IRF3 activation to induce innate immune gene (MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells) expression and that concomitantly suppress dengue virus2 RNA to levels. KIN1408 also exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses^{[1][2]}.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Probiotics Antimicrob Proteins. 2023 Aug 25.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Green RR, et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. *Genom Data*. 2016 Feb 1;7:290-2.
- [2]. Sowmya Pattabhi, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. *J Virol*. 2015 Dec 16;90(5):2372-87.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA